SRSF9 promotes cell proliferation and migration of glioblastoma through enhancing CDK1 expression.

Glioblastoma (GBM) is a highly aggressive and prevalent brain tumor that poses significant challenges in treatment. SRSF9, an RNA-binding protein, is essential for cellular processes and implicated in cancer progression. Yet, its function and mechanism in GBM need clarification. Bioinformatics analysis was performed to explore differential expression of SRSF9 in GBM and its prognostic relevance to glioma patients. SRSF9 and CDK1 expression in GBM cell lines and patients' tissues were quantified by RT-qPCR, Western blot or immunofluorescence assay. The role of SRSF9 in GBM cell proliferation and migration was assessed by MTT, Transwell and colony formation assays. Additionally, transcriptional regulation of CDK1 by SRSF9 was investigated using ChIP-PCR and dual-luciferase assays. The elevated SRSF9 expression correlates to GBM stages and poor survival of glioma patients. Through gain-of-function and loss-of-function strategies, SRSF9 was demonstrated to promote proliferation and migration of GBM cells. Bioinformatics analysis showed that SRSF9 has an impact on cell growth pathways including cell cycle checkpoints and E2F targets. Mechanistically, SRSF9 appears to bind to the promoter of CDK1 gene and increase its transcription level, thus promoting GBM cell proliferation. These findings uncover the cellular function of SRSF9 in GBM and highlight its therapeutic potential for GBM. © 2024. The Author(s).

Citation

Chunyuan Luo, Juan He, Yang Yang, Ke Wu, Xin Fu, Jian Cheng, Yue Ming, Wenrong Liu, Yong Peng. SRSF9 promotes cell proliferation and migration of glioblastoma through enhancing CDK1 expression. Journal of cancer research and clinical oncology. 2024 Jun 06;150(6):292

Mesh Tags

Substances

PMID: 38842611

search → result